RxSight Dirección
Dirección controles de criterios 1/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Aziz Mottiwala
Chief Executive Officer (CEO)
n/a
Compensación total
| Porcentaje del salario del CEO | n/a |
| Permanencia del CEO | less than a year |
| Participación del CEO | n/a |
| Permanencia media de la dirección | 1.8yrs |
| Promedio de permanencia en la Junta Directiva | 5.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Actualización de narrativa • Jul 24
RXST: Future Returns Will Rely On Alcon Collaboration Revenue Contribution
Analysts trimmed their RxSight price targets to $6.50, down from prior levels around $7.50 to $8.00, citing weaker Q2 preliminaries, reduced annual and 2026 guidance, softer utilization trends, and a longer lead time before the new ALC collaboration can contribute. Analyst Commentary Analysts tracking RxSight are focusing on how recent Q2 trends and updated guidance may affect the company’s growth profile, execution risk, and valuation over the next few years.
Actualización de narrativa • Jul 10
RXST: Alcon Partnership Will Offset Weaker Utilization And Guidance Cuts
Analysts have cut the RxSight price target to $6.50, reflecting reduced fair value estimates and lower profit margin expectations after weaker Q2 preliminaries, softer utilization trends, and trimmed guidance. Analyst Commentary Bearish analysts are signaling a more cautious stance on RxSight after the Q2 preliminary update, with lower price targets and concerns around utilization, guidance, and competitive pressures.Seeking Alpha • Jul 08
RxSight: Alcon Deal Reshapes The Long-Term Growth Story
Summary RxSight faces near-term headwinds from competitive trialling, softer procedure volumes, and slowing standalone sales but maintains a constructive long-term outlook. The Alcon collaboration shifts RXST toward a higher-margin, royalty-driven platform, expanding TAM and validating its differentiated Light Adjustable Lens technology. Preliminary 2Q26 results show $32–34M in revenue, with $5–7M from Alcon, strong cash reserves ($209M), and improved gross margin guidance (73–75%) despite lowered core sales expectations. Valuation remains deeply discounted (EV/sales 0.2x), reflecting market skepticism over standalone growth, but long-term optionality and leverage from the Alcon deal underpin the bull case. Read the full article on Seeking Alpha
Actualización de narrativa • Jun 26
RXST: Reaffirmed 2026 Guidance Will Support Stronger Long-Term Margin Profile
Analysts have revised their price target on RxSight to $11.00 from $13.35, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E expectations. What’s in the News for RxSight RxSight reiterated full year 2026 revenue guidance in a range of $120 million to $135 million, in line with previous guidance.Actualización de narrativa • May 03
RXST: Future Returns Will Rely On 2026 Revenue Guidance Reset
Analyst price targets on RxSight have been reset in a tight range around $9 to $10, as analysts adjust models following Q4 results and the company's 2026 revenue outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the updated 2026 revenue outlook of US$120m to US$135m as providing a clearer foundation for modeling, which helps support price targets clustered in the US$9 to US$10 range.Actualización de narrativa • Apr 18
RXST: Future Returns Will Rely On Reset 2026 Revenue Guidance
Analysts have trimmed RxSight's fair value estimate from about $10.21 to $9.93, reflecting recent price target adjustments after Q4 results and updated 2026 revenue guidance. Analyst Commentary Recent Street research around RxSight centers on updated price targets and the new 2026 revenue outlook, with opinions clustering around a more cautious but still engaged stance.Actualización de narrativa • Apr 04
RXST: Future Returns Will Rely On New CFO And 2026 Revenue Guidance
Analysts now see RxSight's fair value edging up to about $10.21 per share from roughly $10.06, reflecting recent price target moves clustered around $9 to $10 as they incorporate updated 2026 guidance, Q4 results and leadership changes into their models. Analyst Commentary Recent research paints a mixed picture around RxSight, with price targets clustered around the high single digits and ratings generally sitting in the middle of the scale.Actualización de narrativa • Mar 20
RXST: Future Returns Will Hinge On New CFO And 2026 Guidance
RxSight's updated fair value estimate has edged slightly lower, in line with Street price targets drifting from around $10 to a range centered near $9 to $10, as analysts factor in refreshed models, 2026 revenue guidance of $120M to $135M, and a mix of target cuts and raises that still cluster around neutral ratings. Analyst Commentary Recent research keeps RxSight broadly in neutral territory, with modest target changes reflecting updated revenue models, the new 2026 guidance range of $120M to $135M, and reactions to management changes.Actualización de narrativa • Mar 06
RXST: Future Returns Will Hinge On New CFO And Execution Quality
Analysts have nudged their blended price target on RxSight lower to about $10.17 from $10.39, reflecting updated views on revenue growth, margins, and future P/E after recent neutral ratings and mixed target moves in the $9 to $10 range. Analyst Commentary Recent research paints a mixed picture for RxSight, with most firms holding neutral ratings and fine tuning their targets in a relatively tight range around the current blended estimate.
Nueva narrativa • Feb 25
Is This Lens Maker Mispriced? A Blind Spot in Plain Sight
RxSight (NASDAQ: RXST), maker of the only cataract lens that can be adjusted post-surgery, could be undervalued by an eye-popping margin More than 70% of RxSight Light Adjustable Lens (LAL) patients reported 20/20 or better vision after receiving the lens. Only 36.3% of non-adjustable lens patients reported the same.Actualización de narrativa • Feb 18
RXST: Future Returns Will Depend On New CFO And Execution Quality
Analysts have raised their average price target on RxSight by $1, citing the recent Piper Sandler move, a neutral initiation that adds coverage breadth, and supportive commentary around the new CFO appointment as reasons for a slightly refined outlook on growth, profitability, and future P/E expectations. Analyst Commentary Recent Street research on RxSight centers on how the new CFO, updated guidance commentary, and modest target changes feed into expectations for execution quality and valuation support.Actualización de narrativa • Feb 03
RXST: Future Returns Will Hinge On New CFO And Execution Confidence
Analysts have nudged their price targets on RxSight modestly higher, with updated models pointing to slightly stronger revenue growth and profit margins and a marginally lower discount rate, while some recent research highlights a move to a $10 target and views the new CFO appointment as supportive of the story. Analyst Commentary Recent research on RxSight reflects a mix of cautious optimism and lingering questions around execution, valuation and the setup after recent share price moves.Actualización de narrativa • Jan 20
RXST: Future Returns Will Depend On Comfortable Revenue And New CFO Execution
Analysts nudged their fair value estimate for RxSight slightly higher to about $10.39 from $10.33, citing better than anticipated recent quarters, a new CFO appointment they view positively, and Street research highlighting revenue that came in ahead of prior expectations, with longer term revenue forecasts described as comfortable. Analyst Commentary Recent Street research paints a mixed but generally constructive picture around RxSight, with attention on execution in recent quarters, the new CFO appointment, and how current revenue trends line up with existing expectations.Artículo de análisis • Jan 10
We're Hopeful That RxSight (NASDAQ:RXST) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Actualización de narrativa • Jan 05
RXST: Future Returns Will Hinge On Sustaining Comfortable Revenue Expectations
Analysts lifted their fair value estimate for RxSight to about $10.33 from $9.89 after a recent price target increase to $10.00. They pointed to a quarter they viewed as better than feared, with revenue of $30m above prior estimates and current Street revenue expectations that they describe as comfortable.Actualización de narrativa • Dec 13
RXST: Future Returns Will Depend On Sustaining Recent Revenue Outperformance
Analysts modestly raised their price target on RxSight to $10 from $8, citing a quarter that exceeded revenue expectations and growing confidence that current Street forecasts for 2026 sales are achievable. Analyst Commentary Analysts are digesting the stronger than expected quarter and reassessing the balance between upside potential and execution risks for RxSight.Artículo de análisis • Dec 12
RxSight, Inc.'s (NASDAQ:RXST) 28% Price Boost Is Out Of Tune With Revenues
Despite an already strong run, RxSight, Inc. ( NASDAQ:RXST ) shares have been powering on, with a gain of 28% in the...Actualización de narrativa • Nov 28
RXST: Future Performance Will Hinge On Sustaining Outperformance Amid Lawsuit Uncertainty
Analysts have increased their price target for RxSight by $2 to $10, citing stronger than expected quarterly revenue performance and a favorable outlook for future estimates. Analyst Commentary Analysts have shared insights following the latest quarterly results for RxSight, highlighting both the optimistic outlook and areas of caution as the company navigates its growth trajectory.Actualización de narrativa • Nov 14
RXST: Future Performance Will Depend On Sustained Revenue Execution And Demand Consistency
Analysts have increased their price target for RxSight to $9.67 from $8.89, citing strong quarterly revenue performance well above expectations and expressing confidence in future revenue estimates. Analyst Commentary Following RxSight's latest quarterly results, analysts have highlighted several factors influencing their revised outlook for the company’s valuation and future performance.Artículo de análisis • Oct 11
Lacklustre Performance Is Driving RxSight, Inc.'s (NASDAQ:RXST) 25% Price Drop
RxSight, Inc. ( NASDAQ:RXST ) shares have had a horrible month, losing 25% after a relatively good period beforehand...Actualización de narrativa • Aug 10
Entry Into European And Asian Markets Will Unlock New Opportunities
RxSight’s consensus price target has been significantly reduced to $8.89 as analysts cite ongoing quarterly misses, slower customer adoption, plateauing utilization rates, and uncertainty around commercial strategy execution. Analyst Commentary Multiple bearish analysts cite consecutive quarterly misses and lowered guidance as primary concerns impacting RxSight's outlook.Artículo de análisis • Aug 07
Investors Don't See Light At End Of RxSight, Inc.'s (NASDAQ:RXST) Tunnel And Push Stock Down 39%
RxSight, Inc. ( NASDAQ:RXST ) shareholders that were waiting for something to happen have been dealt a blow with a 39...Artículo de análisis • Jul 19
Time To Worry? Analysts Just Downgraded Their RxSight, Inc. (NASDAQ:RXST) Outlook
Market forces rained on the parade of RxSight, Inc. ( NASDAQ:RXST ) shareholders today, when the analysts downgraded...Artículo de análisis • Jun 18
The Price Is Right For RxSight, Inc. (NASDAQ:RXST)
When you see that almost half of the companies in the Medical Equipment industry in the United States have...Nueva narrativa • May 08
South Korea And UK Approvals Will Expand Market Adoption
International expansion and regulatory approvals are poised to significantly boost revenue by entering new markets and enhancing clinical support.Artículo de análisis • Apr 04
RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Artículo de análisis • Mar 08
RxSight, Inc. (NASDAQ:RXST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
To the annoyance of some shareholders, RxSight, Inc. ( NASDAQ:RXST ) shares are down a considerable 27% in the last...Artículo de análisis • Feb 28
RxSight, Inc. (NASDAQ:RXST) Just Reported, And Analysts Assigned A US$44.80 Price Target
Shareholders might have noticed that RxSight, Inc. ( NASDAQ:RXST ) filed its full-year result this time last week. The...Artículo de análisis • Dec 06
The Price Is Right For RxSight, Inc. (NASDAQ:RXST)
You may think that with a price-to-sales (or "P/S") ratio of 13.3x RxSight, Inc. ( NASDAQ:RXST ) is a stock to avoid...Seeking Alpha • Nov 29
RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye
Summary RxSight's light adjustable lenses [LAL] continue to gain traction in the $6 billion-plus cataract surgical market. In their Q3 earnings report, RxSight announced that 24,554 LALs were sold in Q3, representing an 80% YoY increase in volume compared to the same period last year. The company's healthy balance sheet supports continued efforts in driving adoption within the U.S. market, while also maintaining the necessary R&D investments to remain innovative in the long run. Due to solid financials and momentum in the large cataract surgery market, RXST is a "buy," but allocate accordingly and be aware of the risks. Read the full article on Seeking AlphaArtículo de análisis • Sep 04
We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Aug 13
Investing In The Future Of Cataract Surgery: The RxSight Advantage
Summary RxSight, Inc. is transforming cataract surgery with the Light Adjustable Lens system, offering postoperative customization for superior vision outcomes. The global cataract devices market is rapidly expanding, with RxSight well-positioned to capitalize on the growing demand for premium IOLs. Impressive financial performance in Q2 2024, with significant revenue growth, gross profit margin improvement, and raised full-year revenue guidance. The stock has 50% upside based on DCF valuation. Read the full article on Seeking AlphaArtículo de análisis • Aug 03
With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For
Unfortunately for some shareholders, the RxSight, Inc. ( NASDAQ:RXST ) share price has dived 27% in the last thirty...Artículo de análisis • Jul 12
Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching
RxSight, Inc. ( NASDAQ:RXST ), is not the largest company out there, but it saw significant share price movement during...Seeking Alpha • Jul 10
RxSight: Great Business Model, Stretched Valuations
Summary Today, we revisit RxSight, Inc., whose stock has nearly quintupled since the end of 2022. The company has a solid business model and loss estimates have come down substantially since we last looked in October of last year. That said, the stock trades north of 15 times forward revenues and RxSight likely doesn't reach profitability until FY2027. Can the stock continue to head higher given that backdrop? An updated analysis follows below. Read the full article on Seeking AlphaArtículo de análisis • Jun 20
A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)
Key Insights The projected fair value for RxSight is US$58.23 based on 2 Stage Free Cash Flow to Equity RxSight's...Artículo de análisis • May 09
RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results
RxSight, Inc. ( NASDAQ:RXST ) just released its latest quarterly results and things are looking bullish. Revenues beat...Artículo de análisis • May 05
RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
Just because a business does not make any money, does not mean that the stock will go down. For example, RxSight...CEO
Aziz Mottiwala (48 yo)
less than a year
Permanencia
Mr. Aziz Mottiwala, MBA, serves as President and Chief Executive Officer at RxSight, Inc. since July 20, 2026 and serves as its Director since July 20, 2026. He served as Chief Commercial Officer at Tarsus...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chief Operating Officer | 7.3yrs | US$2.85m | 0.20% $ 499.0k | |
| Chief Business Development Officer | 11.3yrs | US$4.97m | 1.21% $ 3.0m | |
| Chief Medical Officer | less than a year | US$4.65m | 2.01% $ 5.0m | |
| President | less than a year | sin datos | sin datos | |
| Chief Financial Officer | less than a year | sin datos | 0.060% $ 150.8k | |
| Vice President of Investor Relations | 2.8yrs | sin datos | sin datos | |
| Executive VP & General Counsel | less than a year | sin datos | sin datos | |
| Executive VP of Clinical & Regulatory Affairs | 4.5yrs | sin datos | sin datos | |
| Executive VP of Quality & Infrastructure Operations | 3.3yrs | sin datos | sin datos | |
| Executive Vice President of International | less than a year | sin datos | sin datos | |
| Executive VP of US Sales & Commercial Strategy | no data | sin datos | sin datos |
1.8yrs
Permanencia media
51yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de RXST no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | less than a year | sin datos | sin datos | |
| Director | 9.8yrs | US$219.99k | 0.14% $ 355.8k | |
| Independent Director | 5.1yrs | US$234.99k | 0.099% $ 247.1k | |
| Independent Director | 11.3yrs | US$234.99k | 0.12% $ 299.2k | |
| Independent Chairman of the Board | 11.7yrs | US$282.49k | 1.33% $ 3.3m | |
| Independent Director | 4.7yrs | US$229.99k | 0.085% $ 214.0k | |
| Independent Director | 5.1yrs | US$239.99k | 0.099% $ 247.1k | |
| Independent Director | 5.1yrs | US$237.49k | 0.099% $ 247.1k | |
| Independent Director | 4.8yrs | US$224.99k | 0.044% $ 109.2k |
5.1yrs
Permanencia media
63yo
Promedio de edad
Junta con experiencia: La junta directiva de RXST se considera experimentada (5.1 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/14 00:41 |
| Precio de las acciones al final del día | 2026/09/14 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
RxSight, Inc. está cubierta por 14 analistas. 10 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Travis Steed | BofA Global Research |
| Michael Gorman | BTIG |
| Xuyang Li | Jefferies LLC |